The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Immune monitoring of blood in advanced gastroesophageal adenocarcinoma patients treated with an anti-MMP9 monoclonal antibody in combination with nivolumab.
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio
 
Makiko Yamashita
No Relationships to Disclose
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takashi Ichimura
Speakers' Bureau - Lilly Japan; Ono Pharmaceutical
Research Funding - Clinico
 
Seiichiro Mitani
Honoraria - Lilly; Merck Serono
 
Toshihiro Kudo
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer Yakuhin
Research Funding - Bayer Yakuhin; Chugai Pharma; Lilly; Ono Pharmaceutical; Yakult Honsha
 
Keisho Chin
No Relationships to Disclose
 
Masato Fukui
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Pankaj Bhargava
Employment - Gilead Sciences
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Sanofi
Consulting or Advisory Role - Dicerna
Patents, Royalties, Other Intellectual Property - Method of use of aflibercept (Inst); Patent for method of use of tivozanib (Inst)
 
Carrie Brachmann
Employment - BeiGene (I); Gilead Sciences; OncoMed (I)
Stock and Other Ownership Interests - BeiGene (I); Celgene; Gilead Sciences; OncoMed (I); Roche (I); Vertex
 
Marianna Zavodovskaya
No Relationships to Disclose